Why Investors Should Buy Moderna Stock
Moderna (NASDAQ:MRNA) has arguably priced in the medium-term proceeds from its vaccine for the novel coronavirus. But Moderna stock does not yet appear to reflect the potential of its other vaccines under development, the promising drugs it can acquire in the future, or its own status as a potential takeover target.
Source: Ascannio / Shutterstock.com
Of course Moderna’s vaccine, MRNA-1273, recently won emergency-use approval (EUA) from the FDA. Moreover, Moderna’s vaccine generated excellent efficacy…